A detailed history of Marshall Wace, LLP transactions in Novo Cure LTD stock. As of the latest transaction made, Marshall Wace, LLP holds 779,670 shares of NVCR stock, worth $19.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
779,670
Previous 497,474 56.73%
Holding current value
$19.8 Million
Previous $8.52 Million 43.01%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.61 - $23.34 $4.41 Million - $6.59 Million
282,196 Added 56.73%
779,670 $12.2 Million
Q2 2024

Aug 14, 2024

SELL
$11.83 - $24.05 $3.22 Million - $6.54 Million
-272,053 Reduced 35.35%
497,474 $8.52 Million
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $5.24 Million - $7.3 Million
422,099 Added 121.49%
769,527 $12 Million
Q4 2023

Feb 14, 2024

BUY
$11.13 - $15.78 $3.16 Million - $4.48 Million
284,067 Added 448.33%
347,428 $5.19 Million
Q3 2023

Nov 14, 2023

SELL
$16.15 - $42.35 $2.47 Million - $6.49 Million
-153,241 Reduced 70.75%
63,361 $1.02 Million
Q2 2023

Aug 14, 2023

BUY
$40.29 - $82.51 $8.08 Million - $16.5 Million
200,516 Added 1246.52%
216,602 $8.99 Million
Q1 2023

May 15, 2023

BUY
$56.44 - $118.81 $907,893 - $1.91 Million
16,086 New
16,086 $967,000
Q2 2022

Aug 15, 2022

BUY
$56.6 - $89.9 $5.93 Million - $9.42 Million
104,760 New
104,760 $7.28 Million
Q1 2022

May 16, 2022

SELL
$60.15 - $84.52 $214,855 - $301,905
-3,572 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$75.08 - $121.99 $268,185 - $435,748
3,572 New
3,572 $268,000
Q1 2021

May 17, 2021

SELL
$124.11 - $190.17 $366,248 - $561,191
-2,951 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$112.16 - $174.14 $330,984 - $513,887
2,951 New
2,951 $511,000
Q2 2018

Aug 14, 2018

SELL
$19.85 - $32.0 $327,525 - $528,000
-16,500 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$19.3 - $23.65 $318,450 - $390,225
16,500 New
16,500 $360,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.66B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.